ITGAM and neoplasm: There were no significant differences in the proportion of immune cell subtypes in 3 × 5 Gy RT-treated tumours versus untreated controls at tumour regrowth end-point, although there was a non-significant increase in proportion of CD11b+Gr1+ myeloid cells (p = 0.072), CD11b+Ly6C-Ly6G+ (p = 0.057) cells, and CD11b+Ly6G+ neutrophils (p = 0.070) in radio-recurrent tumours versus controls (Fig. 4b).